PDE5A and benign prostatic hyperplasia: The examined treatments, including alpha receptor blockers, 5-alpha reductase inhibitors, PDE5 inhibitors, anticholinergics, beta-3 agonists, and combination therapies, offer a nuanced approach to address the multifaceted nature of BPH.